Evaluation of the Abbott ARCHITECT i2000 sirolimus assay and comparison with the Abbott IMx sirolimus assay and an established liquid chromatography-tandem mass spectrometry method.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Sirolimus is indicated for prophylaxis treatment to prevent solid organ rejection. Due to intrapatient and interpatient variabilities in pharmacokinetics, risk of concentration-related toxicity, risk of noncompliance, and a high likelihood of drug-drug interactions, therapeutic drug monitoring of sirolimus is essential. There are several methodologies used clinically to monitor sirolimus, ranging from immunoassay to tandem mass spectrometry, each with potential strengths and limitations. The purpose of our study was to validate the Abbott ARCHITECT i2000 sirolimus assay.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Ther Drug Monit

Title: Therapeutic drug monitoring

Publisher: Ovid Technologies (Wolters Kluwer Health)

ISSN (Electronic): 1536-3694

ISSN (Print): 0163-4356

Publication date (Electronic): Aug 2011

Volume: 33

Issue: 4

Affiliations

[1 ] Department of Pathology, University of Utah Health Sciences Center, Salt Lake City, Utah, USA.

Article

DOI: 10.1097/FTD.0b013e3182263981

PubMed ID: 21743377

SO-VID: d0788c71-962f-4872-b8be-a099d084498d

History

Data availability:

Comments

Comment on this article

scite_

Cited by 4

See all cited by